Cost-Benefit Analysis of Using A Single Dose of Tranexamic Acid in Degenerative Lumbar Scoliosis Patients Undergoing Long-Segment Spinal Fusion Surgery: A Retrospective Study

23 August 2021: Clinical Research

Lei Yuan ^123BCE* , Yu Jiang ^123BD* , Yinhao Liu ^123BF , Yan Zeng ^123ADF* , Zhongqiang Chen ^123A , Weishi Li ^123B

DOI: 10.12659/MSM.930352

Med Sci Monit 2021; 27:e930352

Table 2 Pricing of TXA and transfused PRBC units in patients with or without intraoperative TXA.

	NTXA (n=119)	TXA (n=54)	P value
Transfusion-treated patients	111 (93.28%)	47 (87.04%)	0.289
PRBC units given during hospital stay	4.91±3.39	3.50±2.34	^**
TXA cost per patient	¥0	¥9.60	–
PRBC unit acquisition-only cost	¥1079.66±746.88	¥770.00±514.17	^**
PRBC unit net acquisition-only cost+TXA cost	¥1079.66±746.88	¥779.60±514.17	^**
PRBC unit total cost	¥1211.81±937.87	¥786.20±525.22	^**
PRBC unit net total cost+TXA cost	¥1211.81±937.87	¥795.80±525.22	^**
Values are presented as the mean±SD, total cost (including acquisition cost+overhead costs) of 1 unit of PRBCs, including materials and labor. TXA – the group that received tranexamic acid; NTXA – the historically recruited no-TXA group; PRBC – packed red blood cells. ^* ^**